Actinium Pharmaceuticals, Inc. - ROE
ATNM
Price:
$1.03
Market Cap:
$32.32M
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and precli...[Read more]
Industry
Biotechnology
IPO Date
2012-12-27
Stock Exchange
AMEX
Ticker
ATNM
PE Ratio
[-1.36]
ROE
[-218.67%]
Current Ratio
[5.89]
Dividend Yield
[0%]
Enterprise Value
[-8296756.00]
Dividend History
The ROE as of June 2026 (TTM) for Actinium Pharmaceuticals, Inc. (ATNM) is -218.67%
According to Actinium Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -218.67%. This represents a change of 124.91% compared to the average of -97.22% of the last 4 quarters.
Actinium Pharmaceuticals, Inc. (ATNM) Historical ROE (quarterly & annually)
How has ATNM ROE performed in the past?
The mean historical ROE of Actinium Pharmaceuticals, Inc. over the last ten years is -178.91%. The current -218.67% ROE has changed 22.22% with respect to the historical average. Over the past ten years (40 quarters), ATNM's ROE was at its highest in in the June 2021 quarter at -6.24%. The ROE was at its lowest in in the March 2026 quarter at -239.67%.
Average
-178.91%
Median
-134.63%
Minimum
-432.56%
Maximum
-33.69%
Actinium Pharmaceuticals, Inc. (ATNM) ROE by Quarter and Year
Discovering the peaks and valleys of Actinium Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 270.52%
Maximum Annual ROE = -33.69%
Minimum Annual Increase = -90.66%
Minimum Annual ROE = -432.56%
| Year | ROE | Change |
|---|---|---|
| 2025 | -432.56% | 270.52% |
| 2024 | -116.74% | -13.00% |
| 2023 | -134.19% | 170.20% |
| 2022 | -49.66% | 47.43% |
| 2021 | -33.69% | -7.02% |
| 2020 | -36.23% | -90.66% |
| 2019 | -387.97% | 44.55% |
| 2018 | -268.41% | 37.94% |
| 2017 | -194.58% | 44.07% |
| 2016 | -135.06% | 41.16% |
Actinium Pharmaceuticals, Inc. (ATNM) Average ROE
How has ATNM ROE performed in the past?
The current ROE of Actinium Pharmaceuticals, Inc. (ATNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-227.83%
5-year avg
-153.37%
10-year avg
-178.91%
Actinium Pharmaceuticals, Inc. (ATNM) ROE vs. Peers
How is ATNM’s ROE compared to its peers?
Actinium Pharmaceuticals, Inc.’s ROE is greater than PDS Biotechnology Corporation (-346.03%), greater than LAVA Therapeutics N.V. (-108.07%), greater than Xilio Therapeutics, Inc. (-117.24%), greater than Tempest Therapeutics, Inc. (-729.89%), greater than OnKure Therapeutics, Inc. (-61.02%), greater than Reviva Pharmaceuticals Holdings, Inc. (-220.39%), greater than FibroGen, Inc. (-234.28%), greater than Kezar Life Sciences, Inc. (-58.35%), greater than Tvardi Therapeutics, Inc. (-64.17%), greater than Annovis Bio, Inc. (-318.08%),
| Company | ROE | Market cap |
|---|---|---|
| -346.03% | $53.30M | |
| -108.07% | $45.77M | |
| -117.24% | $57.80M | |
| -729.89% | $5.46M | |
| -61.02% | $61.26M | |
| -220.39% | $2.08M | |
| -234.28% | $36.69M | |
| -58.35% | $53.86M | |
| -64.17% | $24.67M | |
| -318.08% | $34.43M |
Build a custom stock screener for Actinium Pharmaceuticals, Inc. (ATNM) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Actinium Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Actinium Pharmaceuticals, Inc. (ATNM) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Actinium Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Actinium Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Actinium Pharmaceuticals, Inc. (ATNM)?
What is the highest ROE for Actinium Pharmaceuticals, Inc. (ATNM)?
What is the 3-year average ROE for Actinium Pharmaceuticals, Inc. (ATNM)?
What is the 5-year average ROE for Actinium Pharmaceuticals, Inc. (ATNM)?
How does the current ROE for Actinium Pharmaceuticals, Inc. (ATNM) compare to its historical average?